Literature DB >> 10848835

Expression of the NUP98/HOXA9 fusion transcript in the blast crisis of Philadelphia chromosome-positive chronic myelogenous leukaemia with t(7;11)(p15;p15).

K Yamamoto1, Y Nakamura, K Saito, S Furusawa.   

Abstract

The t(7;11)(p15;p15) translocation is a recurrent aberration observed in acute myeloblastic leukaemia (AML) and chronic myelogenous leukaemia (CML). It has been shown that the NUP98 gene at 11p15 is fused with the HOXA9 gene at 7p15 in AML with t(7;11). We report the first case with CML expressing the NUP98/HOXA9 fusion transcript. A 27-year-old Japanese man was initially diagnosed as in the chronic phase of Philadelphia-positive CML. At the diagnosis of myeloid blast crisis, the karyotype evolved to 46, XY, t(7;11)(p15;p15), t(9;22)(q34;q11). Reverse transcriptase polymerase chain reaction identified the NUP98/HOXA9 transcript, suggesting that the NUP98/HOXA9 fusion protein could play a critical role in the progression to blast crisis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10848835     DOI: 10.1046/j.1365-2141.2000.02003.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  15 in total

1.  Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia.

Authors:  Benjamin J Frisch; John M Ashton; Lianping Xing; Michael W Becker; Craig T Jordan; Laura M Calvi
Journal:  Blood       Date:  2011-09-28       Impact factor: 22.113

2.  β-Arrestin2 mediates the initiation and progression of myeloid leukemia.

Authors:  Mark Fereshteh; Takahiro Ito; Jeffrey J Kovacs; Chen Zhao; Hyog Young Kwon; Valerie Tornini; Takaaki Konuma; Minyong Chen; Robert J Lefkowitz; Tannishtha Reya
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-05       Impact factor: 11.205

Review 3.  NUP98 fusion in human leukemia: dysregulation of the nuclear pore and homeodomain proteins.

Authors:  Takuro Nakamura
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

4.  Imaging hematopoietic precursor division in real time.

Authors:  Mingfu Wu; Hyog Young Kwon; Frederique Rattis; Jordan Blum; Chen Zhao; Rina Ashkenazi; Trachette L Jackson; Nicholas Gaiano; Tim Oliver; Tannishtha Reya
Journal:  Cell Stem Cell       Date:  2007-11       Impact factor: 24.633

5.  Graft-versus-leukemia (GVL) against mouse blast-crisis chronic myelogenous leukemia (BC-CML) and chronic-phase chronic myelogenous leukemia (CP-CML): shared mechanisms of T cell killing, but programmed death ligands render CP-CML and not BC-CML GVL resistant.

Authors:  Catherine Matte-Martone; Srividhya Venkatesan; Hung Sheng Tan; Ioanna Athanasiadis; Julia Chang; Jovana Pavisic; Warren D Shlomchik
Journal:  J Immunol       Date:  2011-07-18       Impact factor: 5.422

6.  Differential requirements for myeloid leukemia IFN-γ conditioning determine graft-versus-leukemia resistance and sensitivity.

Authors:  Catherine Matte-Martone; Jinling Liu; Meng Zhou; Maria Chikina; Douglas R Green; John T Harty; Warren D Shlomchik
Journal:  J Clin Invest       Date:  2017-06-12       Impact factor: 14.808

7.  A case of acute myeloid leukemia with t(7;11)(p15;p15) mimicking myeloid crisis of chronic myelogenous leukemia.

Authors:  Keiki Kawakami; Setsuko Miyanishi; Kazuhiho Nishii; Eiji Usui; Tetsuya Murata; Isaku Shinsato; Hiroshi Shiku
Journal:  Int J Hematol       Date:  2002-07       Impact factor: 2.490

Review 8.  Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies.

Authors:  Nicole L Michmerhuizen; Jeffery M Klco; Charles G Mullighan
Journal:  Blood       Date:  2020-11-12       Impact factor: 22.113

Review 9.  Stem cell maintenance and disease progression in chronic myeloid leukemia.

Authors:  Takahiro Ito
Journal:  Int J Hematol       Date:  2013-04-04       Impact factor: 2.490

10.  Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.

Authors:  Benjamin S Braun; David A Tuveson; Namie Kong; Doan T Le; Scott C Kogan; Jacob Rozmus; Michelle M Le Beau; Tyler E Jacks; Kevin M Shannon
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.